Literature DB >> 29603921

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Wassim Kassouf1, Armen Aprikian1, Fred Saad2, Rodney H Breau3, Girish Kulkarni4, David M Guttman5, Ken Bagshaw5, Jonathan Izawa6, Libni Eapen7, Adrian Fairey8, Alan So9, Scott North10, Ricardo Rendon11, Srikala S Sridhar12, Fadi Brimo13, Peter Chung14, Darrel Drachenberg15, Yves Fradet16, Niels Jacobsen8, Chris Morash3, Bobby Shayegan17, Geoffrey Gotto18, Alex Zlotta4, Neil Fleshner4, D Robert Siemens19, Peter C Black9.   

Abstract

Entities:  

Year:  2018        PMID： 29603921      PMCID： PMC6118052          DOI： 10.5489/cuaj.5246

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  41 in total

1.  Are Canadian urology residency programs fulfilling the Royal College expectations?: A survey of graduated chief residents.

Authors:  Bassel G Bachir; Armen G Aprikian; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

2.  Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital.

Authors:  Rajal B Shah; Jeffrey S Montgomery; James E Montie; Lakshmi P Kunju
Journal:  Urol Oncol       Date:  2012-05-17       Impact factor: 3.498

3.  Role of Inter-Observer Variability and Quantification of Muscularis Propria in the Pathological Staging of Bladder Cancer.

Authors:  Francesca Giunchi; Riccardo Panzacchi; Elisa Capizzi; Riccardo Schiavina; Eugenio Brunocilla; Giuseppe Martorana; Antonietta D'Errico; Michelangelo Fiorentino
Journal:  Clin Genitourin Cancer       Date:  2016-01-22       Impact factor: 2.872

4.  Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system.

Authors:  Faysal A Yafi; Armen G Aprikian; Simon Tanguay; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

5.  Impact of second opinion pathology in the definitive management of patients with bladder carcinoma.

Authors:  T R Coblentz; S E Mills; D Theodorescu
Journal:  Cancer       Date:  2001-04-01       Impact factor: 6.860

6.  The role of pathology review of transurethral bladder tumor resection specimens in the modern era.

Authors:  Michael C Lee; Howard S Levin; J Stephen Jones
Journal:  J Urol       Date:  2010-01-20       Impact factor: 7.450

7.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

8.  An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec.

Authors:  Nader Fahmy; Wassim Kassouf; Suganthiny Jeyaganth; Moamen Amin; Salaheddin Mahmud; Jordan Steinberg; Simon Tanguay; Armen Aprikian
Journal:  Can Urol Assoc J       Date:  2008-04       Impact factor: 1.862

9.  Longer wait times increase overall mortality in patients with bladder cancer.

Authors:  Girish S Kulkarni; David R Urbach; Peter C Austin; Neil E Fleshner; Andreas Laupacis
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

10.  Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.

Authors:  Faraj El-Gehani; Scott North; Sunita Ghosh; Peter Venner
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862
View more
  4 in total

1.  Building a Canadian Translational Bladder Cancer Research Network.

Authors:  Madhuri Koti; David M Berman; D Robert Siemens; Dirk Lange; Edwin Wang; Paul Toren; Bernhard J Eigl; Céline Hardy; Robert Purves; Vincent Fradet; Yves Fradet; Jose Mansure; Wassim Kassouf; Peter C Black
Journal:  Can Urol Assoc J       Date:  2020-10       Impact factor: 1.862

2.  Improving outcomes of radical cystectomy: A call for passive over active regionalization.

Authors:  Girish S Kulkarni
Journal:  Can Urol Assoc J       Date:  2020-04-01       Impact factor: 1.862

3.  Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.

Authors:  Peter C Black; Nimira Alimohamed; Wassim Kassouf; John L Gore; Kathy D McCoy; Brad H Nelson; Daniel D De Carvalho; Rodney J Ouellette; Ferg Devins; Tony Cornacchia; D Robert Siemens; David M Berman; Srikala S Sridhar; Girish Kulkarni
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

Review 4.  A Narrative Review of the Patient Journey Through the Lens of Non-communicable Diseases in Low- and Middle-Income Countries.

Authors:  Ratna Devi; Komal Kanitkar; R Narendhar; Kawaldip Sehmi; Kannan Subramaniam
Journal:  Adv Ther       Date:  2020-10-14       Impact factor: 4.070
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.